4-bromo-3-(methylthio)aniline | 609783-75-7

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 4-bromo-3-(methylthio)aniline
• 英文别名: 4-Bromo-3-methylsulfanylaniline
• CAS: 609783-75-7
• 化学式: C₇H₈BrNS
• 分子量: 218.117
• InChiKey: QPHIBIUAQNGVGD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  51.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-bromo-3-(methylthio)aniline 在 吡啶 、 盐酸 、 sodium hydride 、 potassium carbonate 、 间氯过氧苯甲酸 、 sodium nitrite 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 反应 36.5h， 生成 4-bromo-N-(4-ethylphenyl)-N-isobutyl-3-(S-methylsulfonimidoyl)benzenesulfonamide
  参考文献：
  名称：

  Route scouting and optimization of a potent sulfoximine-based inverse agonist of RORγt

  摘要：

  During our research looking for novel inverse agonists of ROR gamma t, we identified a potent sulfoximine-based modulator as one of our pre-clinical candidates for the topical treatment for psoriasis. Herein, we describe the various routes we evaluated during the lead generation and optimization phases and the final route chosen for scale-up to deliver the first 100 g of API. (C) 2018 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2018.08.043
• 作为产物：
  描述：

  2-溴-5-硝基苯胺 在 盐酸 、 sodium tetrahydroborate 、 铁粉 、 氯化铵 、 sodium hydroxide 、 sodium nitrite 作用下， 以 甲醇 、 水 为溶剂， 反应 5.0h， 生成 4-bromo-3-(methylthio)aniline
  参考文献：
  名称：

  Route scouting and optimization of a potent sulfoximine-based inverse agonist of RORγt

  摘要：

  During our research looking for novel inverse agonists of ROR gamma t, we identified a potent sulfoximine-based modulator as one of our pre-clinical candidates for the topical treatment for psoriasis. Herein, we describe the various routes we evaluated during the lead generation and optimization phases and the final route chosen for scale-up to deliver the first 100 g of API. (C) 2018 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2018.08.043

文献信息

• Benzamide derivatives
  申请人：Imazaki Naonori

  公开号：US20050182040A1

  公开（公告）日：2005-08-18

  A compound represented by formula (1): wherein X is a single bond or a substituted or unsubstituted lower alkylene group; Z is a saturated or unsaturated monocyclic hydrocarbon ring group or the like; and each of R 1 , R 2 , R 3 and R 4 , which may be the same or different, is a hydrogen atom, a halogen atom, a nitro group, a cyano group, a carboxyl group, a substituted or unsubstituted alkyl group, or the like, a prodrug of said compound, or a pharmaceutically acceptable salt of said compound or prodrug has inhibitory effect on Rho kinase and hence is useful for treating diseases which are such that morbidity due to them is expected to be improved by inhibition of Rho kinase and secondary effects such as inhibition of the Na + /H + exchange transport system caused by the Rho kinase inhibition, for example, hypertension.

  一种由公式（1）表示的化合物：其中X是单键或取代或未取代的较低烷基链；Z是饱和或不饱和的单环烃基环或类似物；而每个R1、R2、R3和R4，可以相同也可以不同，是氢原子、卤素原子、硝基、氰基、羧基、取代或未取代的烷基或类似物，该化合物的前药，或该化合物或前药的药学上可接受的盐具有抑制Rho激酶的作用，因此可用于治疗因抑制Rho激酶而预计疾病的发病率得到改善的疾病，例如高血压，并且由于Rho激酶抑制所引起的Na+/H+交换转运系统的抑制等二次效应。
• BENZAMIDE DERIVATIVES
  申请人：Sumitomo Pharmaceuticals Company, Limited

  公开号：EP1500643A1

  公开（公告）日：2005-01-26

  A compound represented by formula (1): wherein X is a single bond or a substituted or unsubstituted lower alkylene group; Z is a saturated or unsaturated monocyclic hydrocarbon ring group or the like; and each of R1, R2, R3 and R4, which may be the same or different, is a hydrogen atom, a halogen atom, a nitro group, a cyano group, a carboxyl group, a substituted or unsubstituted alkyl group, or the like, a prodrug of said compound, or a pharmaceutically acceptable salt of said compound or prodrug has inhibitory effect on Rho kinase and hence is useful for treating diseases which are such that morbidity due to them is expected to be improved by inhibition of Rho kinase and secondary effects such as inhibition of the Na+/H+ exchange transport system caused by the Rho kinase inhibition, for example, hypertension.

  由式（1）代表的化合物： 其中 X 是单键或取代或未取代的低级亚烷基； Z 是饱和或不饱和的单环烃环基或类似物；以及 R1、R2、R3 和 R4（可以相同或不同）中的每一个是氢原子、卤素原子、硝基、氰基、羧基、取代或未取代的烷基或类似物，所述化合物的原药、或所述化合物或原药的药学上可接受的盐对 Rho 激酶有抑制作用，因此可用于治疗因抑制 Rho 激酶而发病率有望得到改善的疾病，以及因抑制 Rho 激酶而导致 Na+/H+ 交换转运系统受到抑制等副作用的疾病，例如高血压。
• Route scouting and optimization of a potent sulfoximine-based inverse agonist of RORγt
  作者：Guillaume Lafitte、Veronique Parnet、Romain Pierre、Catherine Raffin、Rodolphe Vatinel、Branislav Musicki、Loic Tomas、Claire Bouix-Peter、Gilles Ouvry、Sebastien Daver、Jean-Marie Arlabosse、Jean-Guy Boiteau、Thibaud Gerfaud、Craig S. Harris

  DOI：10.1016/j.tet.2018.08.043

  日期：2018.10

  During our research looking for novel inverse agonists of ROR gamma t, we identified a potent sulfoximine-based modulator as one of our pre-clinical candidates for the topical treatment for psoriasis. Herein, we describe the various routes we evaluated during the lead generation and optimization phases and the final route chosen for scale-up to deliver the first 100 g of API. (C) 2018 Elsevier Ltd. All rights reserved.